Gallup Poll Finds 11% of Americans Now Take GLP-1 Drugs as Obesity Rate Declines

The United States is witnessing a population-level shift in public health that was considered highly unlikely just a decade ago. According to a comprehensive new Gallup poll released this week, 11 percent of American adults are currently taking a GLP-1 medication for weight loss. This represents a staggering increase from just 3 percent in 2024, translating to tens of millions of individuals actively using these therapies. The surge in adoption has coincided with a historic public health milestone: the national obesity rate has declined to 36.4 percent, stepping down from a record high of 39.9 percent in 2022.[1]

This statistical reversal marks one of the most rapid transformations in modern medical history. For decades, public health officials have struggled to contain rising obesity rates through lifestyle interventions and public awareness campaigns, largely to no avail. The introduction and widespread adoption of GLP-1 receptor agonists—such as semaglutide and tirzepatide—have fundamentally altered the trajectory of the nation's metabolic health. Gallup's researchers noted that the decline in obesity inversely tracks with the increased usage of these medications, providing compelling population-level evidence of their efficacy.[2]

The ripple effects of this pharmacological intervention are already visible in chronic disease statistics. After fifteen years of steady increases, the percentage of Americans diagnosed with diabetes has finally leveled off, holding steady at 13.5 percent since 2023. Because diabetes is a lifelong condition that can be managed but not cured, a declining obesity rate would theoretically stabilize rather than reduce the total percentage of diagnosed adults. This stabilization suggests that the wave of new GLP-1 prescriptions is successfully preventing pre-diabetic patients from crossing the threshold into full-blown type 2 diabetes.[3]

However, the rapid expansion of the weight-loss drug market has created a bifurcated landscape for patients. While 68 percent of GLP-1 users report taking FDA-approved brand-name medications like Wegovy, Ozempic, or Zepbound, a growing 19 percent are turning to custom-mixed compounded versions. This split has ignited a fierce debate within the medical community regarding safety, accessibility, and the economics of healthcare. As patients navigate this complex environment, they are forced to weigh the trade-offs between official pharmaceuticals and off-brand alternatives.[1][2]

For brand-name GLP-1 medications, the primary argument centers on guaranteed safety, rigorous clinical testing, and standardized dosing. Drugs manufactured by pharmaceutical giants like Novo Nordisk and Eli Lilly have undergone years of double-blind, placebo-controlled trials to secure approval from the Food and Drug Administration. Patients using these official auto-injectors receive a precise, verified dose of the active pharmaceutical ingredient, accompanied by a proprietary delivery mechanism designed to minimize user error.[1]

Against brand-name medications, the central drawback is the staggering financial burden. Without comprehensive insurance coverage, the out-of-pocket cost for drugs like Wegovy or Zepbound can easily exceed $1,000 per month. Even for those with insurance, prior authorization requirements are notoriously strict, and many employers have opted to exclude weight-loss medications from their corporate health plans to contain costs. This financial barrier effectively gates the most reliable treatments behind a wall of wealth and premium healthcare access.[1]

The evidence supporting the brand-name approach is undeniable. Clinical data consistently demonstrates that patients on official semaglutide or tirzepatide regimens can achieve 15 to 20 percent body weight reduction over a year, alongside significant improvements in cardiovascular health and blood pressure. The Gallup data reflects this success, showing that the most dramatic shifts in eating behavior and weight reduction are occurring among working-age adults who have the means to access these specific brand-name prescriptions.

Conversely, for compounded GLP-1 alternatives, the main benefit is immediate accessibility and affordability. Compounding pharmacies mix their own versions of semaglutide or tirzepatide, often selling them for a fraction of the brand-name price. During periods when official drugs are listed on the FDA's shortage list, compounding pharmacies are legally permitted to produce these alternatives to meet patient demand. For millions of Americans priced out of the official market, compounded drugs represent the only viable path to pharmacological weight management.[1][3]

Against compounded alternatives, the risks include a lack of regulatory oversight, potential contamination, and unverified efficacy. The FDA has issued multiple warnings regarding compounded GLP-1s, noting that some pharmacies use salt forms of semaglutide—such as semaglutide sodium—which have not been proven safe or effective. Because these custom mixtures do not undergo the same rigorous quality control as brand-name drugs, patients face a higher risk of incorrect dosing, bacterial contamination, or receiving a product that simply does not work.[1][3]

The evidence driving the compounded market is purely economic. According to the Gallup poll, 35 percent of patients currently taking compounded GLP-1s previously used a brand-name drug but abandoned it. When asked why they switched, 66 percent cited the prohibitive cost of the official medication, while 34 percent pointed to a loss of insurance coverage. This data clearly illustrates that the migration toward unapproved alternatives is a symptom of systemic pricing failures rather than a preference for the compounded product itself.[1]

Beyond the direct medical implications, the widespread adoption of both brand-name and compounded GLP-1s is reshaping the broader economy. The food and beverage industry is already tracking shifts in consumer behavior, as the medications fundamentally alter appetite and craving profiles. With one in nine American adults now eating differently due to pharmacological intervention, analysts predict long-term structural changes in demand for ultra-processed foods, snacks, and sugary beverages.

The demographic breakdown of GLP-1 usage also reveals important nuances. The Gallup research indicates that the drugs are highly effective across most age groups, with one notable exception: adults aged 65 and older. In this demographic, the reported effectiveness of the medications is lower, suggesting that the physiological response to GLP-1 receptor agonists may diminish with age, or that older adults face different metabolic hurdles that these specific drugs cannot fully overcome.

Public awareness of these treatments has reached near-universal levels. The poll found that 91 percent of U.S. adults now know that GLP-1 medications can be used for weight loss, up from 80 percent just two years ago. This cultural saturation means that the demand for these drugs is unlikely to plateau anytime soon. As awareness grows, the pressure on pharmaceutical companies to increase supply—and on insurers to expand coverage—will only intensify.[1]

Despite the overwhelmingly positive macro trends, medical professionals continue to emphasize that GLP-1 drugs are not a standalone cure for metabolic disease. The medications can cause significant side effects, including severe nausea, gastrointestinal distress, and potential muscle loss if not paired with resistance training. Furthermore, clinical studies indicate that patients who stop taking the drugs often regain a substantial portion of the lost weight, highlighting the need for long-term adherence and simultaneous lifestyle modifications.[2]

Ultimately, brand-name GLP-1 medications fit well when patients have robust insurance coverage, can comfortably afford the out-of-pocket costs, or prioritize the guaranteed safety and rigorous oversight of FDA-approved pharmaceuticals. They are the optimal choice for individuals who want the exact formulation backed by peer-reviewed clinical trials and delivered via a standardized, error-proof injector pen.[1]

Compounded GLP-1 alternatives fit well when patients face insurmountable financial barriers, lack insurance coverage, or cannot access brand-name drugs due to national shortages. However, they do not fit when patients have access to official channels, or when they are unable to verify the credentials, testing standards, and ingredient sourcing of the specific compounding pharmacy providing the medication.[1][3]